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Abstract 
ABO blood group antigens are expressed either on the surface of red blood cells either on a 
variety of other cells. Based on the available knowledge of the genes involved in their 
biosynthesis and their tissue distribution, their polymorphism has been suggested to provide 
intraspecies diversity allowing to cope with diverse and rapidly evolving pathogens. 
Accordingly, the different prevalence of ABO group genotypes among the populations has 
been demonstrated to be driven by malaria selection. In the similar manner, a particular ABO 
blood group may contribute to favour life-extension via biological mechanisms important for 
surviving or eluding serious disease. In this review, we will suggest the possible association 
of ABO group with age-related diseases and longevity taking into account the biological role 
of the ABO glycosyltransferases on some inflammatory mediators as adhesion molecules. 
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Introduction 
There are accumulating evidences that the ABO blood antigens might play a key role in 
various human diseases [1]. Historically, the ABO phenotype was one of the first marker 
involved in cancer susceptibility [2,3], whereas the first association between Human 
Leukocyte Antigens (HLA) and disease was described more recently: the association 
involved a cross-reactive group of HLA-B antigens and Hodgkin’s disease [4]. However, the 
identification of large numbers HLA-associated diseases counterpart our increased 
understanding of the genetic complexity of the HLA system and its extensive polymorphism 
[5], whereas data for ABO antigens are yet not so clear. The ABO molecules represent a 
complex membrane antigens widely expressed both on the surface of red blood cells (RBC) 
and many other cells extending the importance and the clinical significance of the ABO 
system beyond the transfusion medicine [6,7]. 
The ABO system 
The ABO antigen system occurs as a result of complex carbohydrate polymorphism mosaic 
of glycoproteins and glycolipids expressed on the surface of cells, or present in secretions, as 
glycan units [6,7]. 
The A and B antigens are inherited as Mendelian characteristics in a co-dominant autosomal 
fashion. These antigens are the enzymatic products of enzymes called glycosyltransferases 
that in turn synthesize the oligosaccharide epitopes. Thus, the A and B antigens are made by 
A and B glycosyltransferase, respectively (A-synthesizing 3-α-N-
acetylgalactosaminyltransferase and the B-synthesizing 3-α-N-galactosaminyltransferase) 
while the O allele does not encode for a functional transferase. In this last case, the acceptor 
substrate, (H antigen: Fuc alpha1- > 2 Gal-) remains without a further modification and the A 
and B determinants are absent on surfaces of cells [6-8]. 
The A and B glycosyltransferases are type II membrane proteins located in the Golgi 
compartment, although soluble forms are found in plasma and other body fluids. The enzyme 
consists of a short transmembrane domain, a stem region and a catalytic domain that extends 
into the Golgi lumen. So, the A and B antigen synthesis occurs during normal glycosylation 
of proteins and lipids in the Golgi compartment. The precursor H substance is synthesized by 
one of two fucosyltransferases depending on the acceptor substrate used. The FUT1 gene that 
encodes the 2-α-fucosyltransferase (α2FucT1) is mainly responsible for the synthesis of the H 
antigen on carbohydrate precursors found on RBC. The closely related FUT2 gene encodes a 
very similar 2-α-fucosyltransferase (α2FucT2) that is expressed in epithelial cells [7,8]. 
As regards the organization of the ABO locus, the gene consists of seven coding exons and it 
is extended on 18 kb of genomic DNA. The sizes of the exons are included in a range of 28–
688 bp, while the two major exons, 6 and 7, have a size of 1062 bp and contain most of the 
coding sequence. The single nucleotide deletion, found in a large number, but not all, of O 
alleles and responsible for the loss of the activity of the enzyme, is located in exon 6. The 
first of the seventh nucleotide substitutions, which distinguish the A, and B transferases, 
resides in coding exon 6. Exon 7 contains six nucleotide substitutions, resulting in four amino 
acid substitutions, that differentiate the A and B transferases [7,8]. 
ABO subgroups are distinguished by decreased amounts of antigens on RBC, so A2 subgroup 
RBC has less antigens than A1 subgroup (and so on for the other A and B subgroups). It is 
important to point out that the amount of antigens depends on glycosyltransferase activity [9]. 
The ABH sugars are found on lipids (approximately 10%) and proteins (approximately 90%) 
on the RBC surface as well as on many different tissues and cell types, including epithelial 
cells that line the lumen of the gastrointestinal, respiratory, and reproductive tracts as well as 
in salivary glands and skin. This wide distribution is a common feature for many of the 
carbohydrate blood groups, which has resulted in the term histo-blood group often being used 
to reflect this wide distribution. Accordingly, it has been suggested that these antigens, as the 
other glycoconjugates, are important mediators of intercellular adhesion and membrane 
signalling [7,8,10]. 
Ageing and longevity 
The ageing and longevity processes are determined by different genetic, epigenetic, 
stochastic and environmental factors. Among others, evidences from epidemiological studies 
on family of twins and long-lived individuals suggest a strong role for genetics. However, if 
genetics covers the 25% of the overall variation in human life span, another 25% is dependent 
on socio-economic factors in childhood, while adulthood and old age, including the socio-
economic status and medical care, events may represent the remaining 50%. In the Western 
world, the development of the social-economics conditions, as medical care and quality of 
life, are responsible of a general improvement of the health population status with a 
consequent reduction of the overall morbidity and mortality, resulting in an overall increase 
of life expectancy [11,12]. 
Ageing can be defined as a decline in performance and fitness with advancing age, creating 
difficulty in adapting to new environmental situations. The post-maturational ageing process, 
in fact, is characterized by a diminished homeostasis and vulnerability of the body, 
responsible for a reduced response to environmental stimuli and stresses that lead to 
increased susceptibility and vulnerability to disease. Therefore, the mortality from all causes 
exponentially increases with age. In Western countries, the mortality rate increases in people 
over the age of 65, when compared with individuals between 25 and 44 years, because of 
heart disease (92 times), cancer (43 times), stroke (more than 100 times), chronic lung 
disease (greater than 100 times) and pneumonia and influenza (89 times), pointing out the 
role of the control of maintenance/repair systems as those involved in oxidative stress and 
immune-inflammatory responses, in the attainment of successful ageing [13-16]. 
Ageing is unnatural and damage is a fact of life. Ageing is not a programmed route but is a 
stochastic process resulting from accumulation of somatic damage implying a systemic loss 
of molecular fidelity. In ageing, the limited investments in maintenance and repair that are 
evolutionarily selected to assure reproduction and parental care brought to a minimal control 
of inflammation and oxidative stress. So, the ageing process is mostly stochastic, whereas the 
genome plays a role in determining longevity, which is regulated by the level of functional 
reserve reached at the time of reproductive age through natural selection. In other words, the 
effect of the duration of life is incidental because the main effect of the genome is to govern 
the events that occur until reproductive maturity [16-18]. 
Accordingly, demographic evidences suggest that longevity may be attained by different 
combinations of genes and environment with quantitative and qualitative differences in the 
different geographical areas where the population-specific genetic factors play a role in the 
longevity phenotype [19,20]. 
In this context, the study of centenarian offspring, a group of healthy elderly people with a 
familiar history of longevity, has helped gerontologists to better identify the correlation 
between genetic profile and hope of a healthy ageing. Previous studies have reported that 
centenarian offspring, like their centenarian parents, have genetic and immune system 
advantages, which reflect a minor risk to develop major age-related diseases, such as 
cardiovascular diseases (CVD), hypertension or diabetes mellitus as well as cancer [21,22]. 
Therefore, as previously stated, it is possible to assume that longevity may be influenced by 
polymorphisms of genes that control the immune-inflammatory responses as well as genes 
that modulate cardiovascular disease and cancer [20,23-25]. 
Different studies performed on mice have suggested that the Major Histocompatibility 
Complex (MHC), known to control a variety of immune functions, is associated with the life 
span of the strains. Hence, several studies have been performed in humans by analysing loci 
that regulate the immune response, as human MHC (HLA) and killer cell immunoglobulin-
like receptor (KIR) genes regulating the cytolytic activity of natural killer cells. On the 
whole, the results suggest that HLA/KIR/longevity associations are population specific, being 
heavily affected by the population-specific genetic and environmental history [26-29]. 
In addition, as previously stated, alleles associated to CVD and cancer susceptibility have 
been shown to be not included in the genetic background favouring longevity, at least in 
some population, depending on the environmental stimuli [20,23]. 
ABO and age related diseases 
Over the time, several studies have tried a possible association between ABO groups and 
diseases although with contrasting results [1,9,30,31]. Many of the performed studies present 
serious challenges because of a number of confounding factors [32]: i) the incorrect sample 
size leading to selection bias and false positive associations (i.e. the lack of statistical power); 
ii) different inclusion criteria, unsuitable mixing of data (cohort effects) referred to people of 
different age, incorrect control matching, i.e. lack of selection from the same target 
population (stratification); iii) linkage disequilibrium, i.e. the associated ABO group may 
play no direct role, and the actual disease-predisposing polymorphism may be in linkage 
disequilibrium with the initially reported ABO association, which merely acts as a marker. 
Therefore, we will here report only the associations that have been confirmed relating to age-
related diseases, cancer and CVD. 
Cancer is generally recognized as an age-related disease [23,33]. In fact, incidence and 
mortality rates of most human cancers consistently increase with age up to 90 years, although 
they thereafter plateau and decline. The largest number of cancer cases occur in over 65 years 
in both sexes: the incidence of cancer is 12–36 times higher in subjects over 65 years 
compared to individuals aged between 25–44 years and 2–3 times more common than people 
aged between 45–64 years. The multistage model of carcinogenesis provides insight into the 
relationship between ageing and carcinogenesis, since ageing could be considered not so 
much as a determinant of cancer but as the condition, which results in a longer duration of 
exposure to carcinogens [23]. However, a low-grade systemic inflammation characterizes 
ageing and this pro-inflammatory status may underlie biological mechanisms responsible for 
age-related inflammatory diseases [14,24]. Clinical and epidemiological studies, in fact, show 
a strong association between chronic infections, inflammation and cancer and indicate that, 
even in tumours not directly linked to pathogens, the microenvironment is characterized by 
the presence of a smouldering inflammation, fuelled both by stromal leukocytes and 
senescent cells characteristic of ageing [23,24,34]. Therefore, the higher incidence of cancer 
in ageing could be due to pro-inflammatory state of ageing [23]. In any case, cancer and 
ageing are both fuelled by the accumulation of cellular damage, so they can simultaneously 
proceed [33]. 
Several studies have looked for the association between ABO blood group and cancer, 
however there are only evidences for pancreatic and gastric cancer [9,30,31]. 
The association with pancreatic cancer can be traced back to the 1960 study of Aird [35] who 
in 620 patients with pancreatic cancer found evidence of some strength that cancer of the 
pancreas is commoner in persons of group A than in persons of groups O or B. Following this 
pioneering study, in the following years many studies have been performed. As reviewed by 
Liumbruno and Franchini [9,30,31], cohort, case–control and meta-analysis studies clearly 
demonstrate the role of ABO blood group in pancreatic cancer. In particular, it is become 
clear the protective effect of O group and the association with A1 allele. The evidence that 
A1 allele, responsible for an increased glycosyltransferase activity, confers greater pancreatic 
cancer risk than A2 allele, focus on the biological role of glycans, as potential mechanism to 
explain the association, since glycoconjugates, such as ABO antigen, are important mediators 
of intercellular adhesion and membrane signalling, which are both critical to the progression 
and spread of malignant cells [10,36]. 
Concerning gastric cancer, also in this case, as stated in the Introduction, the pioneering study 
was performed by Aird [2], which in 1953 on 3,632 patients, highlighted a 20% increase of 
carcinoma of the stomach in group A as compared to group O. As discussed by Liumbruno e 
Franchini [9,30,31], most of the studies have confirmed that the risk of gastric cancer in 
blood group A is significantly higher than in non-A groups. Concerning the mechanisms, it 
has to point out that ABO blood group is a risk factor for progression towards gastric cancer 
in patients with Helicobacter pylori (Hp) infection, since in the gastric epithelium, the ABO 
blood groups antigens are one of the major functional receptor for Hp [36,37]. The 
association seems to be highly dependent on Hp cytotoxin associated gene (CagA) status, 
which is responsible for the secretion of the CagA virulence protein that, injected in the host 
cell cytosol, plays a relevant role in the precancerous lesion development. This might account 
for the lack of association in studies that did not take into account the prevalence of Hp 
infection in the population under study [36]. 
As regards age-related CVD, an important role is played by atherosclerotic disease, one of the 
main causes of mortality worldwide. Atherosclerosis is a chronic, progressive, multifactorial 
disease mostly affecting large and medium-sized elastic and muscular arteries: fatty-streak 
lesions are initiated by the accumulation of monocytes in subendothelial spaces, where they 
develop into lipid-laden macrophages, otherwise known as foam cells. Currently, multiple 
independent pathways of evidences suggest this pathological condition as a peculiar form of 
inflammation, triggered by cholesterol-rich lipoproteins and other noxious factors, such as 
cigarette smoke, diabetes mellitus and hypertension. Inflammation seems, indeed, to be the 
prevalent process of atherosclerosis, evocated by multiple risk factors and responsible for the 
altered arterial biology associated with atherosclerosis complications [20,38,39]. 
The initial stimulus inducing the inflammatory process has not yet been fully identified. 
However, endothelial dysfunction plays a crucial role in inflammation evocation. Several 
causes are associated with endothelial dysfunction, including the major number of traditional 
atherosclerosis risk factors, i.e. elevated low density lipoprotein values, free radicals caused 
by cigarettes smoking, hypertension, diabetes, elevated levels of homocysteine. Infections 
caused by Chlamydia pneumoniae, Herpes simplex virus, Cytomegalovirus and Hp also have 
been claimed to play a key factors in the disease. Thus, atherosclerosis may be considered as 
a characteristic response both to endothelium injury and to the consequent endothelial 
dysfunction. Endothelial dysfunction leads to compensatory responses modifying the normal 
homeostatic properties of the endothelium and favouring the expression of adhesion 
molecules, which, by binding to various classes of leukocytes, play a key role in the 
atherosclerotic process [20,38-41]. 
Complex interactions among the resident endothelial cells, the smooth muscle cells and the 
infiltrating monocytes and T lymphocytes determine the progression of fatty streaks into 
vascular lesions that block the normal blood flow and ultimately end into rupture of the 
atherosclerotic plaque, leading to either myocardial infarction or stroke [20,38,39]. 
However, the inflammatory process has a strong heritable component. Thus, the analysis of 
the genes that are key nodes of the inflammatory response might in part clarify the 
pathophysiology of atherosclerosis and its complications [14,20,24]. 
Several studies have documented the influence of ABO blood groups on plasma Willebrand 
factor (VWF) levels, hence of factor VIII plasma levels. ABH oligosaccaride structures have 
been identified on the N-linked oligosaccharide chains of VWF located in the A1 domain, 
which contains the binding site for platelet glycoprotein Ib. The VWF levels are 
approximately 25% higher in individuals who have a blood group other than O and it might 
depend on endothelial A, B glycosyltransferase enzymes, which generate A and B antigens, 
on the existing VWF “H” oligosaccharides. This addition to VWF might, in turn, influence its 
blood level [9,31,42-44]. 
On this basis, it is not surprising that a possible association between CVD and ABO blood 
group has been pointed out by several case–control, retrospective and meta-analysis studies. 
Although, most studies show an increased risk for CVD in subjects carrying non-O blood 
groups, there are conflicting results suggesting that the issue of the association between ABO 
blood group and CVD need further investigations [9,31]. On the other hand, large-scale 
genomic studies (GWAS) have revealed a central role for ABO antigens and blood levels of 
inflammatory mediators as soluble adhesion molecules, demonstrating that group O 
individuals show higher levels of inflammatory mediators. This might be due to 
glycosyltransferases activity, which might negatively influence shedding/cleavage of 
inflammatory molecules from the endothelium [9,20,31,45,46], see also below. In any case, 
this could explain the inconsistent results obtained. 
ABO and longevity 
ABO antigens have been known for a long time and yet their biological meaning is still 
largely obscure [1,6]. Based on the available knowledge of the genes involved in their 
biosynthesis and their tissue distribution, their polymorphism has been suggested to provide 
intraspecies diversity allowing to cope with diverse and rapidly evolving pathogens [1,6]. 
Accordingly, the different prevalence of ABO group genotypes among the populations has 
been demonstrated to be driven by malaria selection [1,47,48]. In the similar manner, a 
particular ABO blood group may contribute to favour life-extension via biologica 
mechanisms important for surviving or eluding serious disease [6]. 
There are only five reports suggesting a possible association between ABO blood groups and 
ageing/longevity features, among those only two performed on centenarians and only one 
performed by molecular methods. In the first one, a significant increase of A blood type was 
observed in the healthy elderly male population over 64 years of age from UK [49], but it is 
not possible to consider this study for the very low age taken into account. In a study carried 
out on a small sample of very longevous Turkish population, no association was found [50]; 
however, the validity of age claims was very questionable because birth certificates were not 
available, so also this study cannot be considered. 
A more recent study investigated the association between blood groups and life expectancy in 
Japanese population [51]. The authors compared frequencies of ABO blood groups in 269 
centenarians living in Tokyo and those in 7153 regionally matched controls. Differences 
between centenarians and controls and between observed and expected frequencies were 
investigated by Chi Square tests. Group B was observed more frequently in centenarians than 
in controls, suggesting that group B might be associated with exceptional longevity. The 
authors suggested that group B individuals are more likely to survive age-related diseases 
rather than escape them, since 33% of the centenarians were free of age-related diseases, but 
this did not correlate with the group B. 
In a further study, to validate these results, Brecher and Hay [52] collected data on the ABO 
blood groups of patients who died in a United States tertiary care hospital over a 1-year 
period. If group B was a marker for a longer lifespan, it would be expected that the 
percentage of group B patients would rise with age at the time of death and those of other 
blood groups would decline. A total of 772 patients were included in the study and data were 
presented as ABO proportion stratified by age. The authors found that the percentage of 
group B patients declined with age, and this result was statistically significant. None of the 
other blood groups showed a statistically significant increase or decrease when plotted 
against decade of death. Overall, these results suggest that group B is not a marker for 
longevity, at least in US. 
We have recently investigated [53] the relationship between ABO group and longevity in a 
small sample of homogeneous Sicilian centenarians (n = 38) and young controls (n = 59). Our 
group of centenarians (age range 100–107) had no cardiac risk factors or other age-related 
diseases. The control group (age range 45–65) was recruited from blood donors and judged to 
be healthy on the basis of clinical history and blood tests (complete blood cell count, 
erythrocyte sedimentation rate, glucose, urea nitrogen, creatinine, electrolytes, C-reactive 
protein, liver function tests, iron, proteins, cholesterol and triglycerides). Samples were 
genotyped by molecular biology to determine ABO blood group and Chi Square analysis was 
used to determine the statistical significance of differences in ABO of centenarians and 
controls. Our pilot study shows a not-significant increase of A1 allele in Sicilian 
centenarians. 
Conclusions 
As previously stated, blood groups seem to influence serum level of soluble adhesion 
molecules in blood stream. In particular, it is interesting to note that levels of serum soluble 
E-selectin, which represents an inflammatory marker of several diseases, including CVD, are 
higher in O/O individuals, whereas a single nucleotide polymorphism in A1 allele is 
associated with low levels of these inflammatory markers. A recent GWAS conducted on 
level of inflammatory markers in the Sardinian population highlighted the association 
between CVD and ABO locus and the association was established between this locus and 
interleukin(IL)-6 gene. Subjects homozygous for G allele in rs657152 SNP, corresponding to 
blood type O carriers, showed higher IL-6 circulating levels respect to non-O carriers, 
although the reason in unknown, reinforcing a relevant involvement of blood group antigens 
in inflammatory process. Indeed, previous studies demonstrated that a variant in ABO genes 
might explain the variation in soluble E-selectin levels [45,46,54-56]. 
As previously stated, several studies show that inflammatory gene variants, responsible for a 
low inflammatory response or a high anti-inflammatory response are associated with 
longevity, avoiding or delaying the onset of CVD [19-21]. In the generation of centenarians 
under study, the control of CVD, in fact plays a key role in the longevity attainment [19-21]. 
So, the Sicilian results, that need to be confirmed in a larger sample of centenarians, also 
taking into account the gender due to its relevance in immune-inflammatory responses [57], 
are in line with the previous statements. So, people carrying A1 allele should be advantaged 
in attaining longevity because of the lower levels of the serum soluble inflammatory marker 
E-selectin linked to this blood group, so avoiding or delaying cardiovascular events. 
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